Bempedoic acid: a promising novel agent for LDL-C lowering

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012).
  Medline CASGoogle Scholar
• 2. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019(139), e1082–e1143 (2018). •• The 2018 cholesterol guideline advises clinicians on how to manage blood cholesterol levels and forms the basis for recommendations discussed in this review.
  Google Scholar
• 3. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019(140), e596–e646 (2019). • The 2019 prevention guideline provides a framework for the prevention of cardiovascular disease and is part of the recommendations discussed in this review.
  Google Scholar
• 4. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372(25), 2387–2397 (2015).
  Medline CASGoogle Scholar
• 5. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376(18), 1713–1722 (2017).
  Medline CASGoogle Scholar
• 6. Schwartz GG, Steg PG, Szarek M et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379(22), 2097–2107 (2018).
  Medline CASGoogle Scholar
• 7. Macchi C, Sirtori CR, Corsini A, Santos RD, Watts GF, Ruscica M. A new dawn for managing dyslipidemias: the era of RNA-based therapies. Pharmacol. Res. 150, 104413 (2019).
  Medline CASGoogle Scholar
• 8. Agarwala A, Shapiro MD. Emerging strategies for the management of atherogenic dyslipidaemia. Eur. Cardiol. 15, 1–3 (2020).
  MedlineGoogle Scholar
• 9. Pinkosky SL, Filippov S, Srivastava RA et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J. Lipid Res. 54(1), 134–151 (2013).
  Medline CASGoogle Scholar
• 10. Pearce NJ, Yates JW, Berkhout TA et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J. 334(Pt 1), 113–119 (1998).
  Medline CASGoogle Scholar
• 11. Pinkosky SL, Newton RS, Day EA et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat. Commun. 7, 13457 (2016).
  Medline CASGoogle Scholar
• 12. Berkhout TA, Havekes LM, Pearce NJ, Groot PH. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem. J. 272(1), 181–186 (1990).
  Medline CASGoogle Scholar
• 13. Highlights of Prescribing Information. (2020). https://pi.esperion.com/nexletol/nexletol-pi.pdf
  Google Scholar
• 14. Filippov S, Pinkosky SL, Lister RJ et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J. Lipid Res. 54(8), 2095–2108 (2013).
  Medline CASGoogle Scholar
• 15. Burke AC, Telford DE, Sutherland BG et al. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR^+/− and LDLR^−/−) Yucatan miniature pigs. Arterioscler. Thromb. Vasc. Biol. 38(5), 1178–1190 (2018).
  Medline CASGoogle Scholar
• 16. A multiple ascending dose study of ETC-1002 in healthy subjects (2019). https://clinicaltrials.gov/ct2/show/NCT01485146
  Google Scholar
• 17. A multiple ascending dose study of ETC-1002 in subjects with mild dyslipidemia (2019). https://clinicaltrials.gov/ct2/show/NCT01105598
  Google Scholar
• 18. Single radiolabeled dose study to investigate the absorption, metabolism and excretion of [14C]-ETC-1002 (2019). https://clinicaltrials.gov/ct2/show/NCT02044627
  Google Scholar
• 19. Gutierrez MJ, Rosenberg NL, Macdougall DE et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and Type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 34(3), 676–683 (2014).
  Medline CASGoogle Scholar
• 20. Thompson PD, Rubino J, Janik MJ et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J. Clin. Lipidol. 9(3), 295–304 (2015).
  MedlineGoogle Scholar
• 21. Thompson PD, Macdougall DE, Newton RS et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J. Clin. Lipidol. 10(3), 556–567 (2016).
  MedlineGoogle Scholar
• 22. Ballantyne CM, Davidson MH, Macdougall DE et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J. Am. Coll. Cardiol. 62(13), 1154–1162 (2013).
  Medline CASGoogle Scholar
• 23. A study of the safety, pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia (2019). https://clinicaltrials.gov/ct2/show/NCT01779453
  Google Scholar
• 24. Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension (2019). https://clinicaltrials.gov/ct2/show/NCT02178098
  Google Scholar
• 25. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg when added to PCSK9 inhibitor therapy (2019). https://clinicaltrials.gov/ct2/show/NCT03193047
  Google Scholar
• 26. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20 mg triplet therapy in patients with elevated LDL-C (2019). https://clinicaltrials.gov/ct2/show/NCT03051100
  Google Scholar
• 27. Lalwani ND, Hanselman JC, Macdougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J. Clin. Lipidol. 13(2), 568–579 (2019).
  MedlineGoogle Scholar
• 28. Assessment of the long-term safety and efficacy of bempedoic acid (CLEAR Harmony OLE) (2019). https://clinicaltrials.gov/ct2/show/NCT03067441
  Google Scholar
• 29. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) in patients with hyperlipidemia and statin intolerant (CLEAR Serenity) (2019). https://clinicaltrials.gov/ct2/show/NCT02988115
  Google Scholar
• 30. Ballantyne CM, Laufs U, Ray KK et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur. J. Prev. Cardiol. 27(6), 593–603 (2019). • One of the Phase III trials of bempedoic acid showing combined effect with ezetimibe.
  MedlineGoogle Scholar
• 31. Laufs U, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J. Am. Heart Assoc. 8(7), e011662 (2019). • Phase III trial of bempedoic acid including many statin intolerant patients.
  MedlineGoogle Scholar
• 32. Ballantyne CM, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 277, 195–203 (2018). • Data from Phase III trial in statin-intolerant patients.
  Medline CASGoogle Scholar
• 33. Ray KK, Bays HE, Catapano AL et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N. Engl. J. Med. 380(11), 1022–1032 (2019). •• Findings from this Phase III trial of bempedoic acid were important in its US FDA approval.
  Medline CASGoogle Scholar
• 34. Goldberg AC, Leiter LA, Stroes ESG et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA 322(18), 1780–1788 (2019). •• Findings from this Phase III trial of bempedoic acid were important in its FDA approval.
  Medline CASGoogle Scholar
• 35. Lalwani ND, Hanselman JC, Macdougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J. Clin. Lipidol. 13(4), 568–579 (2019).
  MedlineGoogle Scholar
• 36. Banach M, Duell BP, Gotto A et al. Efficacy of bempedoic acid: a pooled analysis of 4 pivotal Phase III clinical trials. Circulation 140, A12268 (2019).
  Google Scholar
• 37. Leiter LA, Banach M, Catapano A et al. Bempedoic acid and glycemic control: a pooled analysis of 4 Phase III clinical trials. Circulation 140, A11417 (2019).
  Google Scholar
• 38. Wang X, Luo S, Gan X, He C, Huang R. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol. Pol. 77(2), 207–216 (2019).
  MedlineGoogle Scholar
• 39. Ference BA, Ray KK, Catapano AL et al. Mendelian randomization study of ACLY and cardiovascular disease. N. Engl. J. Med. 380(11), 1033–1042 (2019). • Mendelian randomization study involving the mechanism of action of bempedoic acid suggests a beneficial effect of this approach to LDL lowering.
  Medline CASGoogle Scholar
• 40. Macchi C, Banach M, Corsini A, Sirtori CR, Ferri N, Ruscica M. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. Eur. J. Prev. Cardiol. 26(9), 930–949 (2019).
  Medline CASGoogle Scholar
• 41. Ruscica M, Tokgözoğlu L, Corsini A, Sirtori CR. PCSK9 inhibition and inflammation: a narrative review. Atherosclerosis 288, 146–155 (2019).
  Medline CASGoogle Scholar
• 42. Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). (2019). https://clinicaltrials.gov/ct2/show/NCT02993406
  Google Scholar
• 43. Esperion completes patient enrollment in the global CLEAR cardiovascular outcomes trial for bempedoic acid. https://www.esperion.com/investors-media/press-releases/
  Google Scholar
• 44. Stroes ES, Thompson PD, Corsini A et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36(17), 1012–1022 (2015).
  Medline CASGoogle Scholar
• 45. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111–188 (2020).
  MedlineGoogle Scholar
• 46. Honigberg MC, Natarajan P. Bempedoic acid for lowering LDL cholesterol. JAMA 322(18), 1769–1771 (2019).
  MedlineGoogle Scholar
• 47. Esperion Announces U.S. FDA acceptance of new drug applications (NDAs) for both bempedoic acid and the bempedoic acid/ezetimibe combination tablet for filing and regulatory review (2019). https://www.esperion.com/investors-media/press releases/
  Google Scholar
• 48. Esperion announces positive CHMP opinion for the marketing authorisation application for the bempedoic acid / ezetimibe fixed dose combination tablet for the treatment of hypercholesterolemia and mixed dyslipidemia (2020). https://www.esperion.com/investors-media/news-releases/news-release-details/esperion-announces-us-fda-acceptance-new-drug-applications-ndas/
  Google Scholar
• 49. Esperion announces positive CHMP opinion for the marketing authorisation application for bempedoic acid for the treatment of hypercholesterolemia and mixed dyslipidemia (2020). https://www.esperion.com/investors-media/news-releases/news-release-details/esperion-announces-us-fda-acceptance-new-drug-applications-ndas/
  Google Scholar